Bio-Optronics Announces Advanced Business Intelligence Reporting for CTMS
February 9, 2018-ROCHESTER, NY-Bio-Optronics, the makers of the market-leading Clinical Conductor clinical trial management system (CTMS) announces the release of an advanced business intelligence (BI) reporting module designed to provide health systems, CROs and other research organizations real-time access to analytics that drive decisions and business growth.
The BI reporting tool, available as a module in Clinical Conductor CTMS, allows users to quickly create recurring and ad-hoc reports that produce clear insights and identify trends that empower business leaders to make confident decisions that positively impact all levels of the research business.
“Clinical research business leaders are expressing a clear need for a tool that quickly and easily organizes their enormous quantities of data into something actionable,” says Kate Yawman, Product Line Manager for Clinical Conductor CTMS. “With just a few clicks, our BI module provides access to the information our users need to run the world’s best research.”
The business intelligence reporting module is available now for users of Clinical Conductor CTMS. Bio-Optronics will be debuting the BI Module at 9th Annual SCOPE Summit, taking place February 12-15, 2018 in Orlando, FL. The Clinical Conductor CTMS team will also be exhibiting at the 12th Annual Clinical Trial Billing and Research Compliance Conference in Orlando, FL from February 26th-27th, and at the 4th European Conference on Clinical Research in Vienna, Austria.
About Bio-Optronics
Bio-Optronics is a leading software and services company that creates user-focused applications for healthcare organizations that positively impact business performance. With applications focused on clinical research, automated resource utilization and patient safety, Bio- Optronics software is used by thousands of healthcare organizations worldwide to simplify complex business processes and enhance overall quality and efficiency.
For more information, visit www.bio-optronics.com or follow @BioOptronics on Twitter or LinkedIn.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
